Crossmark

Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry

Crossref DOI link: https://doi.org/10.1186/s13569-019-0114-5

Published Online: 2019-04-02

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Call, Jerry W. http://orcid.org/0000-0001-9110-8241
Wang, Yu

Montoya, Denisse

Scherzer, Norman J.

Heinrich, Michael C.
License Information

Text and Data Mining valid from 2019-04-02
More Information

Article History

Received: 21 January 2019

Accepted: 29 March 2019

First Online: 2 April 2019

Change Date: 7 May 2019

Change Type: Correction

Change Details: The legends for Figs. 3 and 5 of the article [1] incorrectly refer to an “all others group”. The corrected legends should read:

Updates are available Correction dated 2019-05-07

Click to view Correction: https://doi.org/10.1186/s13569-019-0117-2